Clinical trials: Nonsmall Cell Lung Cancer Stage III
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Carcinoma, Non-Small-Cell Lung
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent…
- Trial name
- NCT00806819
- Testing
- Nintedanib (BIBF1120), Pemetrexed, B12
- Where
- 163 sites in United States, Argentina and 30 more
- Volunteers
- 718 people
- Sponsor
- Boehringer Ingelheim
Stage III NSCLC
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
A Phase Ib, Open-label, Single-center study to assess the safety of cancer-immunotherapy induction with Tremelimumab and Durvalumab prior to Chemoradiotherapy in the treatment of locally advanced NSCLC.
- Trial name
- Induction (NCT04287894)
- Testing
- Durvalumab, Tremelimumab, Pemetrexed
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- The Netherlands Cancer Institute
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer.
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
- Trial name
- NCT03819296
- Testing
- Best Practice, Biospecimen Collection, Endoscopic Procedure
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Neoplasms
GILT Docetaxel - Non-Small Cell Lung Cancer
Primary Objective: To compare response rate between genotypic groups and control group. Secondary Objective: To determine the safety, time to treatment failure and survival in control and genotypic arms.
- Trial name
- NCT00174629
- Testing
- Docetaxel/DDP, docetaxel/gemcitabine
- Where
- 3 sites in Germany, Spain and 1 more
- Volunteers
- 449 people
- Sponsor
- Sanofi
Non Small Cell Lung Cancer
Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer
This is an open-label, single-arm, phase II, multi-center clinical trial. Thirty patients will be enrolled in this trial to investigate the pathological complete response rate defined as the absence of residual tumor in lung and…
- Trial name
- NeoTAP01 (NCT04304248)
- Testing
- Albumin-bound paclitaxel, Carboplatin, Toripalimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hao Long
Non-Small-Cell Lung Carcinoma
Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)
Locally advanced non-small cell lung cancer, NSCLC, (Stage III) is potentially curable with aggressive combined modality therapy (chemotherapy and radiation).
- Trial name
- NCT00136864
- Testing
- PET Diagnostic Imaging
- Where
- 5 sites in Canada
- Volunteers
- 310 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
This phase Ib/II trial studies the side effects and best dose of trametinib when given together with pembrolizumab and to see how well they work in treating patients with non-small cell lung cancer that has come back and spread…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT03225664
- Testing
- Pembrolizumab, Pharmacokinetic Study, Trametinib
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Carcinoma, Lung Non-Small Cell Carcinoma
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
This trial studies how well dyadic yoga intervention works in improving physical performance and quality of life in patients with stage I-IV non-small cell lung or esophageal cancer undergoing radiotherapy and their caregivers.
- Conditions
- Esophageal Carcinoma, Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8
- Trial name
- NCT03948100
- Testing
- Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Stage IB-IIIA Non-small Cell Lung Carcinoma
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without…
- Trial name
- ADAURA (NCT02511106)
- Testing
- AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
- Where
- 238 sites in United States, Australia and 23 more
- Volunteers
- 682 people
- Sponsor
- AstraZeneca
Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
Phase I/II trial to study the effectiveness of combining GTI-2040 with docetaxel in treating patients who have recurrent, metastatic, or unresectable locally advanced non-small cell lung cancer, prostate cancer, or other solid…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Non-small Cell Lung Cancer
- Trial name
- NCT00074022
- Testing
- GTI-2040, docetaxel, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin), Non-Small-Cell Lung Carcinoma
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
From Protocol v3.0 dated 16Jun2022. This is an international, multicenter, open-label, multiple cohort, First in Human, phase 1b clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any…
- Trial name
- NCT04990479
- Testing
- GAd-PEV, MVA-PEV
- Where
- 7 sites in Belgium, Spain and 1 more
- Volunteers
- 7 people
- Sponsor
- Nouscom SRL
Non-Small Cell Lung Cancer, Radiation Induced Lung Injury (RILI)
Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
Currently, the standard of care treatment for newly diagnosed, inoperable stage III non-small cell lung cancer is radiotherapy (RT) with concurrent chemotherapy, followed by immune checkpoint inhibitors (ICI).
- Trial name
- P4-PACIFIC (NCT06634056)
- Testing
- Pentoxifylline, α-Tocopherol
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- University Health Network, Toronto
NSCLC
Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC
Increasing ("boosting") the radiation dose for patients with non-small cell lung carcinoma to the individual maximal dose which can safely be given.
- Trial name
- PET Boost (NCT01024829)
- Testing
- Radiotherapy
- Where
- 7 sites in Belgium, Denmark and 3 more
- Volunteers
- 150 people
- Sponsor
- The Netherlands Cancer Institute
Non-small Cell Lung Cancer
Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
This randomised, multi-center, controlled trial is designed to assess the efficacy and safety of icotinib with concurrent radiotherapy versus chemotherapy with concurrent radiotherapy in non-small cell lung cancer
- Trial name
- NCT02215356
- Testing
- Icotinib with concurrent radiotherapy, Chemoradiotherapy
- Where
- 26 sites in China
- Volunteers
- 120 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer
This phase II trial compares repeat radiation therapy (RT) to standard drug treatment alone in treating patients with stage II-III non-small cell lung cancer (NSCLC) that has come back after initial radiation at or adjacent to…
- Conditions
- Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT07835789
- Testing
- Biospecimen Collection, Computed Tomography, Immunotherapy
- Volunteers
- 138 people
- Sponsor
- NRG Oncology
Pulmonary Hypertension
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
In the radiotherapeutic treatment of lung cancer, the dose that can be safely applied to the tumour is limited by the risk of radiation induced lung damage. This damage is characterized by parenchymal damage and vascular damage.
- Trial name
- MRI-HART (NCT02377934)
- Testing
- Cardiac Magnetic Resonance Imaging (MRI)
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- University Medical Center Groningen
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lung Cancer
S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004011
- Testing
- carboplatin, paclitaxel, conventional surgery
- Where
- 287 sites in United States, Canada
- Volunteers
- 354 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. ISIS 3521 may help kill more cancer cells by making tumor cells more sensitive to chemotherapy.
- Trial name
- NCT00017407
- Testing
- ISIS 3521, carboplatin, paclitaxel
- Where
- 2 sites in United States
- Sponsor
- Ionis Pharmaceuticals, Inc.